ITB and RMID Osaka University are Collaborating to Produce Vaccine
BANDUNG, itb.ac.id – Institut Teknologi Bandung (ITB) partnering with Osaka University, Japan, to produce Covid-19 vaccine. The collaboration agreement was signed by Vice Rector of Research and Innovation, Prof. I Gede Wenten, Ph.D and Head of Research Institute for Microbial Diseases (RMID) Osaka University, Prof. Masato Okada, Ph.D. on Thursday (4/3/21).
The main purpose of this partnership is to do research and development on Covid-19 vaccine. Scope of this MoU on the outline is improving the production and analysis of new vaccine models which are even more precise and accurate. The collaboration will begin by arranging technical proposal between the vaccine team of ITB and RMID Osaka University.
Prof. Wenten said that he hopes this partnership will give a solution to the health crisis in the world because of Covid-19 pandemic, which involves multidisciplinary sciences.
ITB was the pioneer of vaccine development and teamed up with the local government and international network. Vaccine team of ITB also contributes to the “Merah Putih” vaccine development which is now being produced in Indonesia. “With collaboration between these two universities, ITB is certain that the vaccine team of ITB and RMID can generate and be the frontier on science development in healthcare technology, healthcare system, and global health governance.
Meanwhile, Head of RMID Osaka University said that his institution has been doing fundamental research for 80 years on epidemiology, immunology, oncology, etc. “At this point we already gave a big contribution on controlling contagious disease and primary disease mechanisms”, he said.
Prof. Masato hopes that this partnership could get realized and the contribution can be done well. He also delivered his gratitude to Indonesian and Japanese government for taking a concrete act with a purpose of improving public health and well-being.
Reporter: Adi Permana
Translator: Aghisna Syifa Rahmani/TPB-SITHS
scan for download